Practical guides · Practical guide

Prioritising a validation backlog: which systems come first?

When the system inventory grows faster than the team, a list of outstanding documents gives little direction. Prioritise the backlog using current risks, operational objectives and the next steps your team can take.

Table of contents

At a glance

How do you prioritise a GxP validation backlog?

Start with actual product, patient and data risks and any immediate measures. Then map evidence gaps, system dependencies and available capacity. Establish a justified sequence with owners and verifiable deliverables. A roadmap organises the work. It does not legitimise unacceptable risks in current operations.

Not every open document carries the same risk

A missing report may indicate that the existing evidence has not yet been consolidated. A missing test, on the other hand, could point to an unresolved critical function. Both points may be listed in the inventory as "validation open," but they carry different implications. Therefore, start with the actual application and existing knowledge.

Capture per system the process, owner, current usage scope, and state of evidence. Distinguish between unknown situations, known gaps, and already assessed findings. An unknown data integrity status should not be automatically rated as low merely because no errors have been reported to date.

Annex 11 provides a risk-based framework for computerised GMP applications. ICH Q10 connects this work to quality management, resources and improvement. The portfolio model below is our planning aid. Its scoring scale is not prescribed by a regulator.

Sources: [1] [2]

Clarify acute usability safety prior to establishing long-term sequence.

First, assess whether a currently unacceptably high risk exists: for example, are incorrect results generated, relevant data uncontrolledly altered, or critical decisions made without appropriate basis? Such circumstances require immediate professional evaluation and appropriate corrective actions. Simply assigning the issue to a quarterly roadmap item is insufficient.

Possible actions range from additional testing and limited usage to suspension of an affected process, depending on the findings. They will be specifically justified and evaluated for effectiveness. A general additional signature does not constitute a universal substitute control for unknown technical failures.

Regulatory deadlines, existing obligations, and ongoing investigations must also be addressed separately. Portfolio decisions must not override these considerations through an internal scoring mechanism. Such framework conditions must be made visible prior to allocating resources across initiatives.

Sources: [1] [2]

Five criteria for a justified sequence link together

First, assess the potential impact on product, patient, and recordkeeping. Second, evaluate the uncertainty of the existing evidence. Third, consider exposure: How frequently and to what extent is the function actually used? Fourth, examine dependencies on other systems. Fifth, evaluate the organizational prerequisites for effective handling.

A simple scale can help structure discussions. However, it should not generate false precision. Multiplications from ambiguous categories yield a number, not automatically correct prioritization. Ensure underlying observations and decisions are clearly documented in plain language.

Strategic objectives are subsequently considered: planned system decommissioning, growth, site relocation, or standardization. A system scheduled for imminent decommissioning may require a different validation and transition approach than a long-term platform. The continued use must nevertheless remain technically justified.

Own portfolio assistance: Observation prior to point value
CriterionQuestion to askUsable information
Process impact Which decision or record is associated with that? Named activity and potential impact
Uncertainty about the evidence What do we know, and what remains unresolved? Existing records and specific gap
Scope of Use How frequently and by whom is the function used? Volume, roles, and actual variants
Dependencies What other initiatives are blocked? Interfaces, shared data, and retirements
Feasibility Which resources and prerequisites are missing? Named bottleneck and next action step

Sources: [1] [2]

Example portfolio: three systems with different next steps

System A is an Excel-based evaluation for batch-level decision-making. The calculation methodology is established, but external data integrations remain unvalidated. System B is a training portal featuring existing functional tests and lacking a final assessment. System C is an ERP legacy system that is scheduled to be replaced as part of a planned migration initiative.

For A, the actual data dependency is first assessed and usage is evaluated on a case-by-case basis until clarity is achieved. For B, existing evidence regarding suitability is reviewed and systematically consolidated. For C, ongoing usage, migration, and historical research are jointly planned. The decision therefore is not three times "perform validation catch-up," but rather three distinct work assignments.

The order can change if new findings arise. If A shows a systematic data error, it becomes a priority finding with the evaluation of already generated results. If B proves itself to be sufficiently proven, the team can narrow down the thesis. A good roadmap shows progress in knowledge.

Own exemplary roadmap according to work result
SystemNext feasible stepResponsibility and Consequence Decision
A · Excel Analysis Review external sources, updates, and decisions System Owner and QA assess usage and scope of validation.
B · Training Portal Assign existing documentation and open criteria Responsible person prepares comprehensible final evaluation
C · ERP-Old system Usage, migration, and archiving scope are binding. Programme lead determines the approved transition path
Common Interdependence User management and role-based access clarification IT Operations provides verified foundation for multiple systems

Sources: [1] [2]

Plan work packages based on results rather than document names

Describe a work package such that its completion is verifiable. "Write URS" is less specific than "aligning critical quality decisions and required data transfers with the departmental stakeholders." Documents can record the outcome, but should not be the sole definition of progress.

For each priority, the responsible party, required input, decision point, and acceptance criteria are identified. Supplement with realistically available capacity. If the same system owner is required as a prerequisite for five projects simultaneously, a lengthy task list does not constitute a feasible plan.

Explicitly plan the investigation work. In cases of unknown documentation status, the first step may be a limited inventory review. Only thereafter can the overall scope be reasonably estimated. A seemingly precise date for undefined work does not lead to better control.

Sources: [2]

Address common root causes within the framework

Recurrent gaps may indicate a common process: unclear supplier handover, missing responsibilities, inconsistent changes, or impractical work instructions. Address not only each system individually. Instead, assess the common foundation that will underpin future processing and operation.

An IT GxP compliance framework establishes responsibilities, traceable decisions, and applicable workflows. It does not replace system-specific justifications. A common template for supplier assessment evaluation may assist, such as determining whether a specific supplier test is relevant; however, the appropriateness of any individual supplier test remains a professional judgment.

Align improvements with the company's strategic objectives. If a platform is expected to serve multiple locations in the future, scalable role and change management procedures are advisable. When a system is retired, focus should be placed on controlled residual usage and data lifecycle management. This avoids creating additional regulatory requirements without clear alignment to operational activities.

Sources: [1] [2]

Track progress and re-prioritize in a verifiable manner

Track more than just the number of completed documents. Appropriate metrics may include evaluated critical functions, resolved high-risk findings, completed process validations, and actual transfer of operational responsibility. Define each metric such that it is not merely a renaming of a task.

Establish an appropriate rhythm for portfolio review. New findings, significant changes, resource loss, or a new regulatory obligation may trigger an earlier reassessment. A delayed priority shall be justified; existing risks must not be overlooked.

The management ultimately requires a clear decision-making framework: current action priorities, agreed-upon usage controls, planned outcomes, and required resources. This enables deliberate and targeted guidance. A large number of red status indicators without proposed decisions provides neither support to management nor to system owners.

Sources: [2] [1]

Project experience and collaboration

Prioritise the validation backlog and document the rationale

With QA and process owners, we prioritise evidence gaps by actual use and the consequences of a wrong decision. A large documentation gap may be less urgent than a small, undetected error in a release process. For the first projects, we identify needed evidence, available staff and controls that can take effect immediately. If a critical use is inadequately controlled, its limits must be decided before further project planning. Moving it down an action list does not address the risk.

Frequently asked questions about Validation backlogs

Should the simplest systems be addressed first?

A rapid conclusion may be justified, but it should not obscure critical risks. First assess the implications and identify any immediate actions required. Only thereafter can well-prepared work packages be processed in parallel, provided the necessary resources are available. Assigning tasks based solely on simplicity is not an appropriate indicator of overall progress.

Can an unvalidated inventory system continue to operate until roadmap processing is completed?

A risk assessment does not replace a required validation. The actual usage, existing evidence, and potential consequences should be evaluated by the relevant subject-matter and quality responsible parties. A decision on interim actions must include effective controls, clear usage boundaries, designated responsibilities, and a defined timeline. Uncontrolled critical processes must not continue solely pending a future processing commitment; if necessary, the affected usage must be suspended. The principle of Annex 11 requires a validated application.

Sources: [1]

Does risk prioritization require a numerical risk score?

Not mandatory. A transparent qualitative assessment may be more appropriate than an artificially precise number. If a score is used, the criteria and limits must be clearly defined. Regulatory obligations or acute findings must not be downplayed by a low numerical value.

How does one address a system that is soon to be decommissioned?

Plan actual residual usage, migration, and historical retention together. It may be prudent to specifically safeguard only the actually remaining usage and to demonstrate the transition under controlled conditions. However, the planned decommissioning does not replace an assessment of current risks.

Sources: [1]

Which metric demonstrates genuine progress?

An appropriate key performance indicator describes a verified state, such as clarified critical functions or effective operational handovers. The mere number of prepared documents may falsely suggest progress. Therefore, complement it with professional outcomes, remaining risks, and concrete next-step decisions.

Sources: [2]

How does one prevent a new validation residue?

Anchor system acceptance, responsibilities, changes, and regular evaluation within an applicable procedure. New initiatives should plan for the need for validation evidence in a timely manner. Common foundations assist but do not replace system-specific decisions and the available capacity for such decisions.

Sources: [1] [2]

Sources and review date

As of October 14, 2026. Regulatory classification and manufacturer responsibilities are separately documented. Examples, test matrices, and templates are standalone reference tools; they are customized for actual usage purposes.

  1. European Commission: EU GMP Annex 11, Computerised Systems (2011)Current version as per EudraLex inventory as of 14.10.2026. Application, risks, operation, and data lifecycle; specific testing proposals are derived independently.
  2. EMA / ICH: Q10 Pharmaceutical Quality System, Step 5 (2008)ICH Q10: Resource Management (2.4), Management Assessment (2.6 and 4.1), and CAPA (3.2.2). The portfolio model, examples, and key performance indicators in the contribution serve as internal planning tools.

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

How we can support you

Daniel Herrmann Consulting combines professional assessment with hands-on work on the specific system. During the first meeting, we clarify your intended use, existing documentation, and the next most appropriate action step.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →